ALVET — Theravet SA Share News
0.000.00%
Last trade - 00:00HealthcareHighly Speculative
Brief: TheraVet Provides Update On 2023 Half-Year Development And Portfolio Strategy
Brief: Theravet Announces 300% Increase In Participating Centers In Its Osteosarcoma Program
Brief: Theravet End-Dec Cash Position Of EUR 3.19 Mln
Brief: Theravet Signs New Distribution Agreement For Its Biocera-Vet With Elvetis
Brief: Theravet Announces Exclusive Distribution Agreement For Biocera-Vet In USA
Brief: TheraVet H1 Brutto Operating Loss Widens To 1.0 Million Euros
Brief: Theravet End-June Available Cash Down At Eur 3.50 Million
Brief: Theravet Lauches Biocera-Vet Product Line In United States
Brief: Theravet Signs Distribution Agreement With Nuzoa, Spanish Launch Ahead of Schedule
Brief: Theravet Signs Distribution Agreement With Veterinary Instrumentation
Brief: Theravet FY Net Loss Widens To EUR 1.3 Million
Brief: Theravet Broadens Portfolio With Innovative Line Of Biological Bone Grafts
Brief: Theravet Presents Positive Results Of Bone Surgery Treatment Biocera-Vet
Brief: TheraVet End-Dec Available Cash Up At EUR 5.6 Mln
Brief: Theravet: Simon Wheeler Appointed Chairman Of Board Of Directors
Brief: TheraVet Launches BIOCERA-VET For Canine Osteosarcoma In Belgium, France, Netherlands
Brief: TheraVet Broadens Its BIOCERA-VET Product Line
Brief: Theravet Extends Exclusive Worldwide Licence With Graftys
Brief: TheraVet Says Is The Subject Of Graftys' Unfounded Requests On VISCO-VET IP